Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases

Rhea-AI Summary

Outlook Therapeutics presents at Eyecelerator@AAO 2021 Conference

ISELIN, N.J., Nov. 3, 2021 - Outlook Therapeutics (Nasdaq: OTLK) announced that CEO C. Russell Trenary will present at the Eyecelerator@AAO 2021 Retina Showcases in New Orleans on November 11, 2021, from 1:10 PM to 1:15 PM EST. The company focuses on developing ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases such as wet AMD and DME. If approved, it could be the only FDA-approved ophthalmic formulation of this drug in various global markets.

Outlook Therapeutics management to present on Thursday, November 11, 2021

ISELIN, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the Eyecelerator@AAO 2021 Conference Retina Showcases being held in New Orleans, Louisiana.

Details for the presentation are as follows:

Company Presentation: Retina Showcases
Presenter: C. Russell Trenary III - President and Chief Executive Officer
Date and Time: Thursday, November 11, 2021, 1:10 PM – 1:15 PM EST

Eyecelerator is a partnership between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS) that aims to connect entrepreneurs, investors, companies and physicians to advance ophthalmic innovation through live conferences, virtual programming and a next-generation networking platform. For more information and to register for this event, please visit Eyecelerator@AAO

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com

FAQ

What is Outlook Therapeutics presenting at the Eyecelerator@AAO 2021 Conference?

Outlook Therapeutics will present on its development of ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases.

When will Outlook Therapeutics' presentation take place?

The presentation will occur on November 11, 2021, from 1:10 PM to 1:15 PM EST.

Who will present on behalf of Outlook Therapeutics?

C. Russell Trenary, the President and Chief Executive Officer, will present at the conference.

What is ONS-5010/LYTENAVA™?

ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab targeted for retinal indications like wet AMD, DME, and BRVO.

What markets could benefit from ONS-5010 if approved?

If approved, ONS-5010 could be marketed in the United States, United Kingdom, Europe, Japan, and other regions.

What is the significance of the Eyecelerator@AAO event?

Eyecelerator@AAO connects innovators in ophthalmology, fostering advancements through networking and collaboration.